Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 1998

View Archived Issues

Targeted cytotoxic LHRH analogues show potential as Rx for breast cancer

Dynavax and Vical crosslicense DNA immunization technology

Company Profile: Penwest

Glaxo Wellcome's R&D pipeline remains full and diverse

Genzyme Molecular Oncology, Schering-Plough collaborate to make gene therapy a reality

Novel antifungal peptides isolated by Hoechst Marion Roussel

Vertex describes new MDR-modulating and neuritogenic agents

HIV protease inhibitor research continues at DuPont Merck

Boehringer Ingelheim develops new antiplatelet agents

BMS claims new beta3-adrenoceptor agonists

Antiviral agents that inhibit virus-host cell fusion pursued by Lilly

Duphar presents new vitamin D analogues

Antiprogestational agents with reduced antiglucocorticoid activity claimed by HHS

Hemodynamic profile of new K+ channel activator

Selective inhibitor of PDGF receptor autophosphorylation from Kirin Brewery

New chelating agent developed by Israeli researchers

Pharmacological profile of broad-spectrum, nonopioid analgesic described by Abbott

Novel antitumor cyanoguanidines with good oral bioavailability

Novel coronary artery disease gene therapy scheduled to enter clinical trials

PDMP analogues studied for malaria inhibition

Potential target for a malaria vaccine identified

Johns Hopkins researchers synthesize antimalarial drug candidates

European filing announced for Savedar (DepoCyt)

Malaria vaccine research under way at Gryphon Sciences

Antischistosomal agent derived from myrrh tested in humans

AHP and SKB to merge?

Combination HCV therapy receives priority classification from FDA

Pfizer to develop Nastech formulation of sleep aid

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...